Pfizer Launches TrumpRx Program To Cut Prescription Costs For Millions Of Americans, Expands Drug Affordability With TrumpRx And GoodRx Partnerships

Pfizer announced the rollout of its medicines on the TrumpRx platform, aiming to lower drug costs and improve access for millions of Americans. The move is part of the company’s broader Most Favored Nation (MFN) agreement with the U.S. government, which is designed to reduce prescription prices for patients while supporting continued pharmaceutical innovation in the country.

Under the program, uninsured patients or those choosing to self-pay outside of insurance can receive discounts averaging 50% and reaching as high as 85% on more than 30 Pfizer medicines. These include many primary care products as well as select specialty brands that treat conditions such as migraines, rheumatoid arthritis, menopause symptoms, atopic dermatitis, and overactive bladder, affecting more than 100 million people nationwide.

“For far too long, Americans have shouldered a disproportionate share of the global cost of innovation to help develop breakthroughs for the entire world,” said Albert Bourla, Chairman and Chief Executive Officer of Pfizer. “As the first pharmaceutical company to support President Trump in addressing this imbalance, we’re proud to continue to work with the administration in ensuring affordability for American patients, while preserving America’s position at the forefront of medical innovation.”

To broaden access, Pfizer is working with GoodRx so patients can take advantage of coupons at most U.S. pharmacies or opt for certain home-delivery options. This partnership is intended to give consumers greater flexibility in how and where they obtain lower-cost treatments.

Pfizer also plans to further expand its PfizerForAll direct-to-consumer platform, first launched in 2024, offering additional tools that allow individuals to manage their healthcare more directly without relying heavily on intermediaries.